LexaGene Holdings Inc. (OTCQB: LXXGF) (TSX-V: LXG), which has developed a first of its kind pathogen detection technology capable of detecting over 28 pathogens in under an hour, including some of the most dangerous bacteria such as salmonella and E.coli. LexaGene believes it’s easier and less expensive technology is a better detection solution, and could play a huge role in the identification of potentially deadly bacteria and viruses.
LexaGene and their investors who have put up over $10M in the last year expect their pathogen detection instrument to significantly reduce instances of food recalls due to the shipping of contaminated food items. In addition, this technology should provide the company with exposure to the $13.5 billion food safety industry that has been struggling with food recalls for decades.
Just recently on October 5th, JBS Tolleson began recalling nearly 7M pounds of “various raw, non-intact beef products” due to an outbreak of salmonella, the US Department of Agriculture’s Food Safety and Inspection Service announced Thursday. The recalled products were packaged between July 26 and September 7 and were sold nationwide under brand names Walmart, Cedar River Farms Natural Beef, Showcase, Showcase/Walmart and JBS Generic. Fifty-seven cases of salmonella illness linked to this outbreak were reported in 16 states between August 5 and September 6. Fourteen patients from this outbreak have been hospitalized, but thankfully no deaths have been reported.
Also in the news was Yuma, Arizona, where E. coli, had contaminated romaine lettuce grown, and distributed nationwide. At least 210 people in 36 states were sickened. Five died and 27 suffered kidney failure. The same strain of E. coli that sickened them was detected in a Yuma canal used to irrigate some crops. The deadly Yuma outbreak underscores that irrigation water is a prime source of foodborne illnesses. In some cases, the feces of livestock or wild animals flow into a creek. Then the tainted water seeps into wells or is sprayed onto produce, which is harvested, processed and sold at stores and restaurants.
Even other food products are affected. After conducting a months-long investigation, the Food and Drug Administration has also recently issued mandatory recall orders for products containing Kratom amidst concerns they triggered a large outbreak of Salmonellosis.
The primary concern is the amount of time it takes to identify the bacteria in items before they are shipped to consumers. However, Industry Leaders are also looking for solutions that Save Time, Money, and Get More Accurate Results so these disasters for the victims, and their businesses, can be averted.
Dr. Jack Regan, CEO of LexaGene, shared his insight in a recent company press release:
“Automation removes the costs associated with paying an individual to manually process the sample. It also removes some of the variability seen when different microbiologists process the same sample, as many have small variations in technique that can quite drastically change the result.
In addition, manual testing is more likely to be prone to false positives due to user-caused cross-contamination. Automated instruments can run 24/7, which is very helpful for plants that are operational 24 hours a day”.
Movement into the Healthcare Sector
On October 19th, 2018 LexaGene Holdings Inc. unveiled a model of its low-cost LX2™ Beta Prototype at the American Association of Veterinary Laboratory Diagnosticians (AAVLD) conference in Kansas City, MO. The biotechnology company plans to apply the technology to help healthcare providers diagnose patients. Currently, healthcare providers collect samples from patients and ship them to an offsite laboratory, a process that usually takes days to send and receive results.
Healthcare Providers will now be able to identify the presence of antibiotic resistant bacteria in an hour. Providers will also be able to treat patients with more targeted therapies while they are still in the facility. The biotechnology company expects the technology to be the world’s first easy-to-use open access rapid pathogen detection system. By using the LX2, vets would no longer have to send samples to labs as they could have results within one hour, helping healthcare professionals and vets find an accurate diagnosis faster.
“The veterinarians at our hospital are happy that LexaGene has listened to our suggestions and are specifically building an instrument to meet our needs in the Emergency/Critical Care and Internal Medicine departments. We currently lack reliable point-of-care diagnostics for infectious diseases and need an instrument that is small enough to fit into our cramped hospital, yet has the screening potential to look for many diseases at once. The fact that LexaGene’s technology will also look for some antimicrobial resistance factors is a huge plus,” said Dr. Samuel Stewart, DVM, DACVECC, Emergency and Critical Care veterinarian at Ethos Discovery.
LexaGene’s CEO, Dr. Jack Regan added:
“Our veterinary partners are thrilled about the increased screening capability of the LX2 and its smaller footprint. Incorporating this technology into a veterinary practice will provide better patient outcomes since the technology also looks for antimicrobial resistance, which will allow clinicians to make more informed decisions on prescribing the appropriate antibiotic. Furthermore, by bringing the testing in-house, practices will tap into a valuable revenue stream that will drive adoption rates.”
The LX2 is the very first fully automated pathogen detection platform that is open-access, empowering end-users to target any pathogen of interest, as they can load their own real-time PCR assays onto the instrument for customized pathogen detection.
The instrument is expected to offer excellent sensitivity, specificity, and breadth of pathogen detection, as well as will be able to process multiple samples at a time, in an on-demand fashion, returning results in about 1 hour. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, and press ‘go’. The company expects to sell its technology in the veterinary diagnostics market, food safety market, and more.
The LX2 System is a low cost, small-footprint instrument perfectly suited for veterinary clinics as it takes less than a minute to initiate automated sample processing. This breakthrough technology will provide practitioners with the information they need to better treat their patients, while also allowing their practice to assume control over an important incremental revenue stream.
The instrument’s ability to return results in just one hour is a drastic improvement over the currently used standard culture methods that require shipping samples to laboratories, where results don’t become available for three or more days. LexaGene’s solution for faster and more accurate results will improve health outcomes, lower the overall cost of care, and lead to increased profitability for the practice.
A Credible Threat to the Food Industry
The CDC estimates that 265,000 STEC infections occur each year in the United States. These outbreaks not only cause illness and even death to consumers, but are devastating to the company that has created the problem. Lexagene’s technology will be able to help prevent these from happening, saving major corporations millions of dollars.
JBS Tolleson Inc October 2018
- JBS Tolleson is recalling 6,500,966 pounds of “various raw, non-intact beef products” due to an outbreak of salmonella the US Department of Agriculture’s Food Safety and Inspection Service announced Thursday.
- Fifty-seven cases of salmonella illness linked to this outbreak were reported in 16 states between August 5 and September 6.
Yuma AZ Lettuce April 2018
- On April 13 the CDC reported its investigation focused on chopped romaine lettuce from the Yuma, Arizona, region.
- The CDC reported a final number of infected people of 197 in 35 states. A total of five deaths have been reported.
I.M. Healthy Brand SoyNut Butter January 2017
- 12 state outbreak of Shiga toxin-producing Escherichia coli
- On March 30, 2017, the FDA says no food products may be sold or distributed by the Dixie Dew Products, Inc. facility in Erlanger, Kentucky
- 32 illnesses have been reported from 12 states
Chipotle November 2015
- Chipotle announces it has closed 43 restaurants in Oregon and Washington.
- The CDC reported that 53 people were infected in nine states.
- It cost them over 3 years of earnings and brought sales down over 15%, sending their stock plummeting.
No Major Corporation wants to go through that, so they are investing in preventative measures.
An Opportune Time to Invest in LexaGene?
In an industry where there are 2.6 billion tests every year, LexaGene’s new instrument is a game-changer. This $13.6 billion market is in desperate need, and LexaGene could help the industry avoid damaging recalls and save lives by catching any pathogens before products hit the shelves.
From an investor’s perspective, there is no better time to get involved.
Their technology is tried-and-tested with over 20 years of development and previous versions used by the National Institute of Health and the Department of Homeland Security in high-profile areas such as the Olympics and Grand Central Station, New York City. The production of LexaGene’s beta product began in October, and this helps to eliminate much of the risk investors face when supporting revolutionary new technologies.
There are risks associated with an early investment like LexaGene, but having raised over $10M in the last year, they are primarily mitigated by its intensive market analysis demonstrating clear pain points and its working alpha prototype. LexaGene is also operating in the biotech market where large acquisitions are commonplace, facilitating a more natural exit strategy for investors.
The fact is that LexaGene’s product will revolutionize safety standards and save lives across America. Early investors who believe in this company and its product will not only make the strongest positive impact with their funds but also reap the greatest rewards.
Visit the company here https://lexagene.com/
Paid advertisement. This communication is a paid advertisement. MoneyNewsNational.com, and their owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by lexagene holdings inc to conduct investor awareness advertising and marketing for lexagene holdings inc. lexagene holdings inc will pay the Publisher up to $140,000 to produce and disseminate this article and certain banner ads. lexagene holdings inc may in the future pay the Publisher additional sums as compensation for other articles and marketing services. This compensation should be viewed as a major conflict with our ability to be unbiased.
Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur.
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment adviser and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.
SHARE OWNERSHIP. The owner of MoneyNewsNational.com owns shares and/or stock options of the featured companies and therefore has an additional incentive to see the featured companies’ stock perform well. The owner of MoneyNewsNational.com will not notify the market when it decides to buy or sell shares of this issuer in the market. The owner of MoneyNewsNational.com will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.
FORWARD-LOOKING STATEMENTS. This publication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. The publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the companies’ actual results of operations. Factors that could cause actual results to differ include, but are not limited to, changing governmental laws and policies, the success of the companies’ drilling excursions, the size and growth of the market for the companies’ products and services, the companies’ ability to fund their capital requirements in the near term and long term, pricing pressures, etc.
INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
INTELLECTUAL PROPERTY. MoneyNewsNational.com is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.
RESAAS Signs Joint Venture With San Francisco Title Technology Company to Tokenize every Property in the United States, backed by Investment Bank US Capital Global to Raise Up To $7 million USD
BREAKING NEWS UPDATE: July 31, 2018 – RESAAS Services Inc. (TSX.V: RSS, OTCQX: RSASF) RESAAS Signs Joint Venture With San Francisco Title...